Immunovant Inc. (IMVT)
NASDAQ (NGS) NASDAQ (NGS) Primary 
IMVT Q3 Loss Wider Than Expected, Stock Down, Pipeline in Focus
Immunovant stock down on dismal third-quarter fiscal 2025 results. It is on track to initiate 10 studies on IMVT-1402 across various autoimmune indications.
A Huge Biotech Purchase Highlights New Year's Insider Buying
The year started off slow as far as insider purchases go.
Immunovant: Continued FcRn Targeting With IMVT-1402 Pivotal Study
Immunovant aims to initiate a pivotal registration study for IMVT-1402 targeting Graves' Disease by the end of 2024, with 4–5 trials in other IgG-mediated autoimmune disorders by March 2025. IMVT-1402 offers deeper IgG suppression without increasing LDL cholesterol like Batoclimab does. Financial caution is advised as Immunovant's cash runway only extends for 12 months, likely necessitating IMVT to make a cash raise in 2025.
Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus
IMVT reports dismal second-quarter fiscal 2025 results. It is on track to initiate several studies on IMVT-1402 across various autoimmune indications.
What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday?
Monday, Immunovant, Inc. IMVT reported results from the Phase 2a trial of batoclimab in Graves' Disease, an immune system condition that affects the thyroid gland. It causes the body to make too much thyroid hormone.
IMVT Stock Up on Upbeat Data From Graves' Disease Study of Batoclimab
Immunovant stock rises on mid-stage study data of batoclimab for Graves' Disease, showing superior efficacy compared to anti-thyroid drug therapy options.
Top 2 Health Care Stocks That May Collapse This Quarter
As of Sept. 9, 2024, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Why Is Immunovant (IMVT) Up 13.8% Since Last Earnings Report?
Immunovant (IMVT) reported earnings 30 days ago. What's next for the stock?
Immunovant (IMVT) Falls as Q4 Earnings Miss, Pipeline in Focus
Immunovant (IMVT) declines 5% on dismal fourth-quarter fiscal 2024 results. The company names IMVT-1402 as its new lead candidate to initiate several studies for autoimmune indications.
Biohaven Crashes After Protein-Degrading Drug Misses Expectations; Immunovant, Argenx Jump
Biohaven stock crashed Wednesday after the company's experimental protein-degrading drug lagged investor expectations.
